Literature DB >> 18163538

Acridine-based agents with topoisomerase II activity inhibit pancreatic cancer cell proliferation and induce apoptosis.

John R Goodell1, Andrei V Ougolkov, Hiroshi Hiasa, Harneet Kaur, Rory Remmel, Daniel D Billadeau, David M Ferguson.   

Abstract

A series of substituted 9-aminoacridines is evaluated for antiproliferative activity toward pancreatic cancer cells. The results indicate that the compounds inhibit cell proliferation by inducing a G1-S phase arrest. A model is also developed that explains the molecular basis to inhibition through a DNA "threading" mechanism. We conclude that the drug-DNA complex formed blocks topoisomerase II binding and activity leading to catalytic inhibition of the enzyme and the induction of apoptosis and programmed cell death.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18163538     DOI: 10.1021/jm701228e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

1.  Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic α-aminophosphonates that act as novel topoisomerase II inhibitors.

Authors:  Yi Ma; Jian-Guo Wang; Bin Wang; Zheng-Ming Li
Journal:  J Mol Model       Date:  2010-11-25       Impact factor: 1.810

2.  Enhanced antiproliferative activity of the new anticancer candidate LPSF/AC04 in cyclodextrin inclusion complexes encapsulated into liposomes.

Authors:  Elisângela A M Mendonça; Mariane C B Lira; Marcelo M Rabello; Isabella M F Cavalcanti; Suely L Galdino; Ivan R Pitta; Maria do Carmo A Lima; Maira G R Pitta; Marcelo Z Hernandes; Nereide S Santos-Magalhães
Journal:  AAPS PharmSciTech       Date:  2012-10-02       Impact factor: 3.246

3.  Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases.

Authors:  Qi Qi; Kunyan He; Min-Heui Yoo; Chi-Bun Chan; Xia Liu; Zhaobin Zhang; Jeffrey J Olson; Ge Xiao; Liya Wang; Hui Mao; Haian Fu; Hui Tao; Suresh S Ramalingam; Shi-Yong Sun; Paul S Mischel; Keqiang Ye
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

4.  Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer.

Authors:  Etchison Ryan; A Jacobson Blake; A Benoit; M Ferguson David; A Kratzke Robert
Journal:  Invest New Drugs       Date:  2012-07-22       Impact factor: 3.850

5.  Evaluating the genotoxicity of topoisomerase-targeted antibiotics.

Authors:  Daniel J Smart; Anthony M Lynch
Journal:  Mutagenesis       Date:  2011-12-07       Impact factor: 3.000

6.  Chiral ruthenium(II) anthraquinone complexes as dual inhibitors of topoisomerases I and II.

Authors:  Jun-Feng Kou; Chen Qian; Jin-Quan Wang; Xiang Chen; Li-Li Wang; Hui Chao; Liang-Nian Ji
Journal:  J Biol Inorg Chem       Date:  2011-08-21       Impact factor: 3.358

7.  Synthesis of acridines by the [4 + 2] annulation of arynes and 2-aminoaryl ketones.

Authors:  Donald C Rogness; Richard C Larock
Journal:  J Org Chem       Date:  2010-04-02       Impact factor: 4.354

8.  Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II.

Authors:  Lisa M Oppegard; Andrei V Ougolkov; Doris N Luchini; Renee A Schoon; John R Goodell; Harneet Kaur; Daniel D Billadeau; David M Ferguson; Hiroshi Hiasa
Journal:  Eur J Pharmacol       Date:  2008-12-03       Impact factor: 4.432

9.  Quinacrine causes apoptosis in human cancer cell lines through caspase-mediated pathway and regulation of small-GTPase.

Authors:  Angela Samanta; Geethanjali Ravindran; Angshuman Sarkar
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

10.  Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II.

Authors:  Ahad A Sadiq; Manish R Patel; Blake A Jacobson; Marco Escobedo; Keith Ellis; Lisa M Oppegard; Hiroshi Hiasa; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2009-01-10       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.